<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-14005094</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-08-08</date_registration>
      <primary_sponsor>Cell Biotherapy Center, Daping Hospital, Third Military Medical University</primary_sponsor>
      <public_title>Effective and safety evaluation of human umbilical cord derived mesenchymal stem cells (HU - MSCs) in severe sepsis or septic shock</public_title>
      <acronym />
      <scientific_title>Effective and safety evaluation of human umbilical cord derived mesenchymal stem cells (HU - MSCs) in severe sepsis or septic shock</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-10-01</date_enrolment>
      <type_enrolment />
      <target_size>Phase I low dose group:5;Phase I moderate dose group:5;Phase I high dose group:5;Phase II experimental group:35;Phase II control group:35;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=4481</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>I+II (Phase I+Phase II)</phase>
      <hc_freetext>severe sepsis or septic shock</hc_freetext>
      <i_freetext>Phase I low dose group:Human umbilical cord derived mesenchymal stem cells (HU - MSCs) ;Phase I moderate dose group:Human umbilical cord derived mesenchymal stem cells (HU - MSCs);Phase I high dose group:Human umbilical cord derived mesenchymal stem cells (HU - MSCs);Phase II experimental group:Human umbilical cord derived mesenchymal stem cells (HU - MSCs);Phase II control group:normal saline with 1% human serum albumin;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xiao He</firstname>
        <middlename />
        <lastname />
        <address>10 Changjiang Branch Road, Yuzhong District, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13658312340</telephone>
        <email>hx_tx@126.com</email>
        <affiliation>Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiang Xu</firstname>
        <middlename />
        <lastname />
        <address>10 Changjiang Branch Road, Yuzhong District, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13637843870</telephone>
        <email>xiangxu@ymail.com</email>
        <affiliation>Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Good adherence to patients and their families with informed consents; 
2. patients of ICU, aged from 16 to 65 years old; 
3. Have a clear diagnosis of severe sepsis and septic shock; 
4. Expected survival time longer than 28 days.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients with uncorrected disease, such as advanced cancer or other terminal illness, the prospective survival period less than 28 days;
2. Patients in the foreseeable dying state;
3. HIV infected with CD4 less than 50/mm3;
4. Have the bone marrow, lungs, liver, pancreas, or history of small bowel transplantation;
5. Chronic renal failure need hemodialysis or peritoneal dialysis;
6. Known or potential of portal hypertension, chronic icteric, chronic liver cirrhosis and ascites;
7. Acute pancreatitis with no clear focal infection;
8. Patient participating or having participated in a clinical trial with another investigational drug Within 30 days before the start of this clinical trial;
9. Patient is pregnant or nursing;
10. Fungal sepsis;
11. History of patient is allergic to biological products, allergic reactions or other serious reaction.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>28-Day All-Cause Mortality;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>self-financed</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-07-31</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>